A Review of Studies of Quality of Life for Chinese-Speaking Patients with Ischemic Heart Disease.

OBJECTIVES

To review published studies of the use of health-related quality-of-life (HRQOL) instruments in patients with ischemic heart disease (IHD) in Chinese-speaking countries/regions, namely, mainland China, Hong Kong, Taiwan, and Singapore.

METHODS

Overlapping searching strategy was used for searching three electronic databases-Cochrane Library, MEDLINE, and Embase-from January 1, 1990, to September 30, 2015. After culling, the identified publications were analyzed according to the publication date, the location where the study was conducted, the disease being studied, and the nature of the study (i.e., whether it was a validation study or an application study).

RESULTS

There were 109 publications identified for review, of which 15 studies (13.8%) were for validation of HRQOL instruments. Among these studies, most were conducted in China. There were 35 instruments applied and validated in the studies. The most commonly used instruments were the Short Form 36-Item Health Survey and the Seattle Angina Questionnaire. Overall, the number of studies using HRQOL instruments has been increasing in recent years. But there were only two disease-specific instruments validated in Chinese patients with IHD-one was a chronic disease-specific instrument (QLICD-GM) and the other an IHD-specific instrument (QLICD-CHD) validated only in limited sample sizes without data on patients with the three IHD subgroup diseases (angina, myocardial infarction, and heart failure). Three disease-specific instruments were validated in patients with IHD in Hong Kong. No instrument was validated in patients with IHD in Taiwan and Singapore. This showed a lack of adequately validated core IHD instruments in Chinese-speaking countries/regions.

CONCLUSIONS

Considering the substantial negative impact of IHD from economical, clinical, and humanistic perspectives, psychometric evaluation of core IHD-specific instruments is still needed in patients with IHD and IHD subgroup diseases in Chinese-speaking countries/regions.